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Abstract All cell types express a great variety of G protein-
coupled receptors (GPCRs) that are coupled to only a limited
set of G proteins. This disposition favors cross-talk between
transduction pathways. However, GPCRs are organized into
functional units. They promote speci¢city and thus avoid unsuit-
able cross-talk. New methodologies (mostly yeast two-hybrid
screens and proteomics) have been used to discover more than
50 GPCR-associated proteins that are involved in building these
units. In addition, these protein networks participate in the
tra⁄cking, targeting, signaling, ¢ne-tuning and allosteric regu-
lation of GPCRs. To date, proteins that interact with the
GPCR C-terminus are the most abundant and are the focus
of this review.
+ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
G protein-coupled receptors (GPCRs) are the most numer-
ous and most diverse type of membrane-bound proteins. They
represent 1^5% (roughly 340 genes) of the invertebrate and
vertebrate (including human) genomes [1^3]. They are classi-
¢ed into at least eight families. These families show no se-
quence similarity and use di¡erent domains to bind a great
variety of ligands (photons, Ca2þ, odorants, tasting molecules
such as bitter or sweet compounds, amino acids, nucleotides,
peptides or proteins), but activate a limited number of heter-
otrimeric G proteins (GKLQ) [2]. There are only 16 GK sub-
units, grouped into four families: GKs, GKi, GKq, GK12/13
[4], ¢ve GL and 12 GQ subunits associated in a functional GLQ
complex. We know little about the molecular mechanisms that
control the speci¢city of association of these subunits into
heterotrimeric complexes. Moreover, a single GPCR can acti-
vate more than one type of G protein. Therefore, one key
question is to know how GPCR-mediated accurate physiolog-
ical responses are generated through speci¢c signaling path-
ways. One obvious response is that each individual cell ex-
presses a limited number of GPCRs and G proteins, although
in most cells, this is not the case. Another response could be
that signaling molecules are organized into physically and
functionally distinct units. This organization would optimize
speci¢city, selectivity and time course of signaling and mini-
mize unsuitable cross-talk between transduction pathways.
The last 5 years of research in the ¢eld have revealed that
numerous proteins involved in cellular signaling contain pro-
tein^protein interaction domains that allow their recruitment
and assembly into large complexes. These include Src homol-
ogy 2 (SH2) and SH3, pleckstrin homology, postsynaptic den-
sity protein of 95 kDa (PSD95)-disc large-zona occludens
(PDZ) and Ena/VASP homology (EVH) domains. The evolu-
tion of multicellular organisms is associated with an increase
in the number of proteins that contain such structural inter-
acting domains, as well as an increase in the number of these
domains per protein.
GPCRs have been found to interact with a wide variety of
proteins containing structural interacting domains [5^8].
These proteins have several important functions. First, they
participate in the targeting of GPCRs to speci¢c subcellular
compartments. Secondly, they are responsible for the cluster-
ing of these receptors with various e¡ectors. Thirdly, they can
regulate GPCR functions in an allosteric manner. GPCR-as-
sociated proteins are known to interact with intracellular
loops, transmembrane and C-terminal domains. To date,
those interacting with the GPCR C-terminus are the most
numerous (more than 40), the best studied and are the focal
point of this review.
2. Methodologies to ¢sh out GPCR-associated proteins
2.1. The yeast two-hybrid system
The yeast two-hybrid system can be used to examine an
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interaction between two proteins of interest. This system can
screen for unknown binding partners of one’s favorite protein
and map protein interaction domains. This system was devel-
oped from the modular structure of the yeast transcription
factor GAL4, which includes a DNA binding domain and a
transcription activation domain. One of the proteins of inter-
est is expressed as a fusion protein with the GAL4 binding
domain, whereas the other is fused to the activation domain.
The interaction of the two proteins reconstitutes a functional
GAL4 transcription factor and induces transcription of re-
porter genes integrated in the region downstream of the
GAL4 binding site [9].
The yeast two-hybrid system allows very sensitive detec-
tion of in vivo protein^protein interactions without directly
handling any protein molecules and has been successfully
used to identify proteins interacting with the cytosolic do-
mains of various GPCRs. However, this system has various
limitations: (1) it enables the detection of binary interac-
tions, but not global characterization of multi-protein net-
works; (2) it is not optimal for the detection of protein^pro-
tein interactions that depend on post-translational modi¢-
cations and interactions between membrane proteins; (3) it
can generate many false positives or negatives and does not
prove the physiological relevance of the identi¢ed interac-
tions.
2.2. Gel overlay assay
The gel overlay assay can be used to examine an interaction
between two favorite proteins in vitro. One protein is pro-
duced as a fusion protein in bacteria, run on sodium dodecyl
sulfate^polyacrylamide gel electrophoresis, blotted onto nitro-
cellulose membranes and then incubated with a second favor-
ite protein in solution. The interaction between the two pro-
teins is detected using an antibody against the protein in
solution.
2.3. Proteomic approaches
Proteomic approaches aim at providing a global character-
ization of protein networks and have already identi¢ed many
of the proteins present in such complexes. They generally in-
clude one puri¢cation step, mostly peptide a⁄nity chromatog-
raphy (but co-immunoprecipitation can also be performed),
followed by one- or two-dimensional polyacrylamide gel elec-
trophoresis separation of proteins. Once separated, the pro-
teins are identi¢ed by mass spectrometry techniques. These
techniques include matrix-assisted laser desorption ioniza-
tion-time of £ight or tandem mass spectrometry (electrospray
quadrupole-time of £ight or ion trap mass spectrometry). Us-
ing the entire C-terminal tail of the serotoninergic 5-hydroxy-
tryptamine 2C (5-HT2C) receptor as bait, we have recently
identi¢ed more than 15 interacting proteins. Some interact
with the PDZ domain recognition motif located at the ex-
treme C-terminus of the receptor, others interact outside this
PDZ motif [10] (Fig. 1). These proteomic approaches should
yield future high-throughput characterization of protein net-
works interacting with any membrane-bound receptor, includ-
ing GPCRs, providing that the speci¢city of the puri¢cation
step is improved by the development of several-step protocols
[11]. However, the task of demonstrating a physiological rele-
vance of any given protein^protein interaction remains critical
using this type of approach.
3. PDZ domain-containing proteins associated with the extreme
C-terminus of GPCRs
Many GPCRs express at their C-terminal extremity a motif
of recognition of PDZ domains (PDZ ligand, Fig. 2). This
includes the last three to four C-terminal amino acids, which
constitute the minimal part of the sequence that binds to PDZ
domains (Fig. 2). PDZ ligands have been divided into three
classes, based on their amino acid sequence: class I (-E-S/T-x-
V/I), class II (-P-x-P) and class III (i-x-P ; where P and i are
hydrophobic and acidic residues, respectively) [12]. It is worth
noting that some PDZ ligands cannot be classi¢ed into these
categories. Here we will not exhaustively comment on PDZ
domain-containing proteins that interact with GPCRs, but
rather focus on proteins that have been studied for their func-
tional roles.
3.1. Role in signaling speci¢city
Protein interacting with C kinase 1 (PICK-1), a protein
originally cloned on the basis of its interaction with protein
kinase C-K (PKC-K), contains a single PDZ domain as well as
a coiled-coil and an acidic domain (Fig. 2) [13]. This PDZ
domain is relatively versatile as it accommodates type I, II
and III PDZ ligands [14^18].
The roles of PICK-1 in metabotropic glutamate receptor
type 7a (mGluR7a) function have been particularly well
studied. The interaction of the PDZ domain of PICK-1 with
the last three amino acids (-LVI) of mGluR7a has been found
to be required for the clustering of this receptor at presynaptic
terminals, but not for its axonal and membrane targeting
[19,20].
In cultured cerebellar granule neurons, mGluR7a selectively
inhibits P/Q type Ca2þ channels and glutamatergic synaptic
transmission via a Go-phospholipase C (PLC)-PKC-depen-
dent cascade [21]. In contrast, another Go-coupled receptor,
mGluR2, which does not bind to PICK-1, inhibits N and L,
but not P/Q type Ca2þ channels. Fig. 3A illustrates a record-
ing of a Ca2þ current and is blocked by L-aminophosphono-
butyrate (L-AP4) (Aa), a speci¢c mGluR7 agonist. The Ca2þ
current is of the P/Q type since the L-AP4 blockade is oc-
cluded by g-Agatoxin (Ab). Chimeras were constructed by
exchanging the C-terminus of these receptors. Chimeric recep-
tors bearing the C-terminus of mGluR7a selectively blocked
P/Q type Ca2þ channels, whereas chimeras bearing the C-ter-
minus of mGluR2 blocked N and L type Ca2þ channels [23].
Moreover, an mGluR7a that harbors point mutations with-
in the PDZ ligand and the mGluR7b splice variant, which
binds weakly to PICK-1, does not block P/Q type Ca2þ chan-
nels. Inhibition of PICK-1 expression by an antisense oligo-
nucleotide suppressed the blockade of P/Q type Ca2þ channels
and inhibition of glutamatergic synaptic transmission by
mGluR7a [22]. Fig. 3B illustrates results on synaptic trans-
mission. Spontaneous synaptic events are recorded in cerebel-
lar granule cells (Fig. 3Ba, control). g-Agatoxin and L-AP4
reduce the frequency of these events but not their amplitude.
This indicates that both compounds reduce the presynaptic
release of glutamate. Fig. 3Bb shows the evolution of the ratio
between the frequency of spontaneous synaptic events before
(Fc : frequency control) and after treatment (F). Note that the
e¡ects of L-AP4 and g-agatoxin are not additive (Fig. 3Bb).
After antisense knock-out of PICK-1, the mGluR7-mediated
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blockade with L-AP4 is suppressed, whereas the blockade
with g-agatoxin is maintained (Bb). These results indicate
that the interaction of mGluR7a with PICK-1 speci¢es the
coupling of the receptor complex to Ca2þ channels at presyn-
aptic terminals (see also Fig. 4). The mechanism by which
PICK-1 promotes the coupling between mGluR7a and the
P/Q type Ca2þ channels remains unknown. An association
between mGluR7a and PKC-K via a PICK-1 homodimer
(formed by an association of their coiled-coil domain) may
be involved in this e¡ect.
The Naþ/Hþ exchanger regulatory factor (NHERF), also
called ezrin-radixin-moesin binding protein of 50 kDa
(EBP50; Fig. 2), has recently been shown to control para-
thyroid hormone 1 (PTH1) receptor signaling. PLC-L1 and
PTH1 receptor interact with the ¢rst and second PDZ
domains of NHERF via their PDZ ligands (-DPTL and
-ETVM, respectively) [24]. In membranes expressing NHERF,
for example in brush border of epithelial renal proximal tu-
bules, PTH1 receptor activates PLC, but not adenylyl cyclase.
However, in cell membranes that do not express NHERF, like
basolateral membranes of these epithelial cells, PTH1 receptor
activates adenylyl cyclase, but not PLC [24]. The ¢rst PDZ
domain of NHERF also interacts with L2-adrenergic (L2-AR),
extracellular nucleotide ATP receptors of P2Y1 type, and U-
opioid receptors and these associations control the activity of
the Naþ/Hþ exchanger [25^27].
The direct coupling between L1-AR and cyclic nucleotide-
Ras guanine exchange factor (CN-Ras GEF) allows L1-AR
Fig. 1. Spatial and functional organization of synaptic multi-protein networks interacting with 5-HT2C receptors. The proteins ¢shed out by a
proteomic approach using the C-terminal tail of the 5-HT2C receptor as bait are depicted. Protein^protein interactions at the presumptive pre-
synaptic and postsynaptic sites are based on published pro¢les and electron microscopy observations.
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activation of Ras. Activation of CN-Ras GEF requires both
the binding of the C-terminus of L1-AR (-SKV) to the PDZ
domain of CN-Ras GEF and the binding of cAMP to its CN
binding site [28].
3.2. Spatial organization of the synapse
The SH3 multiple ankyrin domain-containing protein
(Shank), also called somatostatin receptor interacting protein
(SSTRIP) or proline-rich synapse-associated protein (ProSAP)
[29,30], is the prototype of the PDZ sca¡olding protein.
Shank spatially organizes metabotropic and ionotropic gluta-
mate receptors at the postsynaptic membrane and provides an
interface between these membrane-bound receptors and the
cytoskeleton [31] (Figs. 2 and 4A). This sca¡olding function
is accomplished thanks to the following protein^protein inter-
actions:
(i) The PDZ domain of Shank interacts with the C-terminus
of guanylate kinase-associated protein (GKAP) which is
linked to the ionotropic glutamate N-methyl-D-aspartate
(NMDA) receptor^PSD95 protein complex (Fig. 4A).
(ii) The SH3 domain of Shank has been proposed to inter-
act with the ionotropic glutamate K-amino-3-hydroxy-5-meth-
Fig. 2. PDZ domain-containing proteins interacting with GPCR C-termini. The PDZ domain-containing proteins are listed and schematically
represented with their di¡erent domains. GPCRs interacting with these proteins are indicated with the sequence of their C-terminal interacting
motif and type of PDZ domain (PDZ I, II, III).
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yl-4-isoxazolepropionic acid (AMPA) receptors via the gluta-
mate receptor interacting protein, GRIP (Fig. 4A) [31].
(iii) The proline-rich domain of Shank interacts with the
EVH domain of Homer proteins [32,33]. Homer proteins
form multimers through interactions of their coiled-coil do-
main and link Shank to mGluR1a/5 and inositol triphosphate
(IP3) or ryanodine receptors [29,34] (Fig. 4A).
(iv) The ankyrin repeat and proline-rich domains of Shank
bind to the actin-associated proteins, fodrin and cortactin,
respectively.
Thus, Shank exhibits a remarkable ability to recruit
mGluR1a/5, NMDA and IP3 receptors as well as other post-
synaptic proteins. Shank also recruits actin and increases the
size of dendritic spines in cultured hippocampal neurons [35].
3.3. Receptor tra⁄cking and targeting
Many PDZ domain-containing proteins regulate receptor
tra⁄cking. NEHRF accelerates the recycling of endocytosed
L2-AR and U-opioid receptors [27]. PSD95 decreases L1-AR
internalization whereas the MAGUK with inverted domain
structure protein (MAGI-2) increases this process [36,37].
Tamalin binds Arno, a GEF for the ADP-ribosylation factor
family (ARF) of small G proteins, and enhances neuritic
growth and cell surface localization of mGluR1a [38].
4. Proteins without PDZ domains
Additional proteins that do not contain PDZ domains bind
to more proximal regions of the GPCR C-terminal tail. They
include both soluble and transmembrane proteins and, as
PDZ domain-containing proteins, control localization and
function of GPCRs.
4.1. Soluble proteins
4.1.1. Proteins with tra⁄cking properties. The dopamine
receptor interacting protein of 78 kDa (DRIP-78) is impli-
cated in the tra⁄cking of dopamine D1 receptor to the plasma
membrane [39]. The interaction of the C-terminal QVAPA
motif of rhodopsin with t-complex testis-expressed 1 (TcTex-
1), a dynein light chain subunit, is required for e⁄cient trans-
port of rhodopsin from the cell body to the outer segment of
rods [40]. Mutations in this sequence are responsible for ret-
initis pigmentosa associated with somatic accumulation of
rhodopsin [41].
4.1.2. Proteins of the cytoskeleton. In accordance with the
localization of GPCRs in physically de¢ned subcellular com-
partments, the C-terminus of these receptors has been shown
to directly or indirectly interact with cytoskeleton proteins.
We have already discussed the Shank^cortactin/fodrin and
rhodopsin^TcTex-1 interactions. In addition, ¢lamin A is a
large actin binding protein that interacts with mGluR5, 7b,
8 and Ca2þ receptors and many other proteins including cav-
eolin [42,43]. Myosin heavy chain IIA interacts with the C-
termini of CCR5 and CXCR4 chemokine receptors in T lym-
phocytes. This association may be involved in T lymphocyte
migration [44]. Finally, 5-HT2C receptors interact with 4.1N,
actin, spectrin and CapZ proteins [10] (see Fig. 1).
4.1.3. Proteins with signaling properties. Ca2þ/calmodulin
and GLQ subunits compete for a common C-terminal binding
sequence of mGluR7 and are involved in the inhibition of
Ca2þ channels by this receptor [45]. The angiotensin recep-
tor-associated protein (ATRAP) binds to angiotensin II type
1 (AT1) receptor and inhibits its coupling to PLC [46]. Src
binds to phosphorylated Ser or Thr of L2-AR, L1-AR and
many other GPCR C-termini, via arrestins. Arrestins also
allow the sca¡olding of other enzymes, such as c-Jun ami-
no-terminal kinase 3 (JNK3), extracellular signal-regulated ki-
nases and apoptosis signal-regulating kinase 1 [8]. The canna-
binoid receptor, CB1, is coupled in an unde¢ned manner to
sphingomyelin hydrolysis through an adapter protein called
factor associated with neutral sphingomyelinase activation
(FAN) [47]. Muskelin binds exclusively to the K splice variant
of the prostaglandin E2 receptor, EP3, controlling its internal-
ization and coupling to the Gi protein [48]. Gravin, the
Fig. 3. PICK-1 is required for presynaptic inhibition of P/Q chan-
nels and glutamate transmission by mGluR. A: (a) Ca2þ currents
elicited by depolarization from 360 to 0 mV, in the absence (con-
trol) and presence of the mGluR7a agonist, L-aminophosphonobuty-
rate (L-AP4; 500 WM), in mGluR7a-transfected cerebellar granule
cells. Note the agonist-induced inhibition of the current. (b) g-Aga-
toxin (Aga) abolished the inhibitory e¡ect of L-AP4, indicating that
the mGluR7-sensitive Ca2þ channels were of the P/Q type. B:
mGluR7a inhibits glutamatergic synaptic transmission. (a) Sponta-
neous synaptic events recorded in a cerebellar granule cell, in the
absence (control) and presence of L-AP4 or g-agatoxin. The inhibi-
tion of the frequency, but not the amplitude of the events by these
drugs indicates that presynaptic P/Q type Ca2þ channels are in-
volved in synaptic transmission and that mGluR7 blocks this neuro-
transmission. (b, left) After inhibition of neurotransmission by L-
AP4, g-agatoxin had no additional e¡ect, indicating that mGluR7
blocked synaptic transmission via inhibition of P/Q type Ca2þ chan-
nels. (b, right) The inhibitory e¡ect of L-AP4 was abolished by
PICK-1 antisense oligonucleotides. This indicates that PICK-1 was
required for the signaling of mGluR7 to the P/Q type Ca2þ chan-
nels. The inhibition induced by g-agatoxin established the presence
of P/Q type Ca2þ channels in the preparation (F/Fc = frequency of
spontaneous synaptic events relative to control) [22,23].
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cAMP-dependent protein kinase-anchoring protein of 250
kDa, is a typical sca¡olding protein interacting with L2-AR,
PKA, PKC, arrestins and calcineurin [8].
4.1.4. Homer proteins, a family of multifunctional proteins
involved in the tra⁄cking, sca¡olding and allosteric regulation
of mGluR1a/5. Homer proteins constitute a protein family
containing an N-terminal EVH domain. This domain interacts
with polyproline sequences (-PPXFX-) of several signaling
and sca¡olding proteins located at glutamatergic postsynaptic
sites (Fig. 4A). These include mGluR1a and mGluR5, Shank
Fig. 4. Functional organization of the glutamatergic synapse. A: Pre- and postsynaptic protein networks associated with mGluR7a (presynap-
tic) and mGluR1a/mGluR5/NMDA (postsynaptic) receptors, respectively. Note that mGluR7 and mGluR1a/mGluR5 are both physically and
functionally coupled to P/Q type voltage-dependent Ca2þ channels and intracellular Ca2þ stores, respectively. B: Homer1a alters mGluR5-medi-
ated Ca2þ responses. (a) Big Kþ channel activity recorded in a cultured cerebellar granule cell transfected with mGluR5. The rapid activation
of the channel by the mGluR1/5 agonist, DHPG, indicates an mGluR5-induced Ca2þ release from intracellular stores. (b) Co-transfection of
mGluR5 with Homer1a increased the latency and amplitude of the agonist-induced Ca2þ response [51,53]. (b,c) In the absence of agonist,
transfection of Homer1a (b) or treatment with a Homer3 antisense oligonucleotide (c) increased the spontaneous activity of the Big Kþ chan-
nel, indicating a constitutive activity of the mGluR1/5 in the presence of Homer1a or after knock-out of endogenous Homer3. Similar results
as those observed with transfected Homer1a were obtained with neuronal activity-induced expression of endogenous Homer1a.
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(see Section 3.2), IP3 receptors, ryanodine receptors, and P/Q
type Ca2þ channels [49]. All Homer proteins, except Hom-
er1a, display self- and hetero-multimerization properties so
that their interaction with target polyproline sequences allows
sca¡olding of mGluR1a/5 with Shank, IP3 receptor, ryano-
dine receptor and P/Q type Ca2þ channels (Fig. 4A). In the
absence of Homer1b/c (such as in cultured cerebellar granule
cells), transfected mGluR5 is retained in somatic intracellular
compartments. Induction of Homer1a protein by high neuro-
nal activity triggers the targeting of the receptor to axon and
dendrites [32,50]. There is evidence to indicate that the induc-
tion of Homer1a inhibits the functions of multimeric Homer
proteins (Homer1b/c, Homer2 or Homer3) and thus acts as a
dominant negative:
1. co-transfection of Homer1b with mGluR5 in cultured cer-
ebellar granule cells induces a speci¢c postsynaptic local-
ization and intracellular retention of the mGluR5^Hom-
er1b complex. Induction of Homer1a by neuronal activity
triggers the transfer of mGluR5 from the intracellular
pools to plasma membrane at these postsynaptic sites [51].
2. Transfection of Homer1a in cerebellar neurons increases
the latency and duration of the mGluR1a- and mGluR5-
mediated intracellular Ca2þ release following application of
dihydroxyphenylglycine (DHPG), a speci¢c mGluR1,5 ag-
onist. This is illustrated in Fig. 4Ba (control) and 4Bb
(after Homer1a transfection) showing the DHPG activa-
tion of Big Kþ channels [51,52]. These e¡ects may result
from the dissociation of the mGluR1a/5^IP3^ryanodine
receptor complex.
3. Activity-dependent induction of Homer1a triggers a consti-
tutive activity (spontaneous G protein activation) of
mGluR1/5 in cerebellar granule cells [53]. Indeed, the in-
teraction of these receptors with Homer3, and probably the
Shank-associated multiprotein complex, keeps mGluR1/5
silent in the absence of agonist. Disruption of this con-
straint, either by neuronal activity-induced Homer1a ex-
pression (Fig. 4Bb) or by antisense oligonucleotide-medi-
ated knock-out of Homer3 (Fig. 4Bc), induces spontaneous
activity of mGluR1a/5. Note that in these experiments, the
Big Kþ channel activity is very high (constitutively active)
in the absence of DHPG.
4.1.5. Proteins with enzymatic activity or transcriptional
activity. Janus kinase/signal transducer and activator of
transcription (JAK/STAT) proteins, the ¢rst elements in cyto-
kine receptor signaling, bind to AT1 and 5-HT2A receptors
[54,55]. The Janus kinase binding motif (-YIPP-) on the AT1
receptor is localized in the proximal region of the receptor C-
terminal tail [56]. The phosphorylation of the tyrosine residue
in this motif promotes its association with the tyrosine phos-
phatase SHP-2 and PLC-Q [57]. The so-called i4 loop (the
additional intracellular loop formed by the C-terminal tail
between transmembrane domain VII and the palmitoylated
cysteines of the C-terminus) of AT1 and endothelin B recep-
tors binds to endothelial nitric oxide synthase (eNOS) and
that of the bradykinin B2 receptor binds to neuronal nitric
oxide synthase and eNOS. Interaction of eNOS with B2 re-
ceptors forms an inhibitory complex likely acting via the
blockade of the £avin to heme electron transfer. This inhibi-
tion is released by receptor ligands [58,59]. Src binds directly
to a polyproline C-terminal domain of L3-AR [60]. Surpris-
ingly, an ATP-generating enzyme, such as creatine kinase,
binds directly to protease-activated receptor 1. This associa-
tion may generate the ATP required for e⁄cient receptor sig-
nal transduction during cytoskeleton reorganization via RhoA
[61]. The C-terminus of the heterodimeric Q-aminobutyric acid
type B (GABA-B) receptor binds to the related transcription
factors, cAMP responsive element binding protein 2 (CREB2)
and activating transcription factor-x (ATFx). Activation of
the receptor allows translocation of CREB2 from the cytosol
to the nucleus [62].
4.2. Transmembrane proteins
It is quite surprising that the C-terminus of GPCRs can
interact with transmembrane proteins. A very well identi¢ed
example is the GABA-B1 and GABA-B2 receptor subunits
which form heterodimers via their C-terminal coiled-coil do-
mains [62]. This interaction unmasks the endoplasmic reticu-
lum retention sequence of GABA-B1 (-RKR-) and allows
transfer of the GABA-B receptor dimer to the plasma mem-
brane. Calcyon, a single transmembrane domain protein, in-
teracts with D1 receptors. In dendritic spines of frontal cortex
pyramidal cells, this interaction allows for a shift from a Gs
protein to a Gs/Gq protein coupling of D1 receptors [63].
Two provocative reports have recently shown that GPCRs
may also have a ‘close a¡air’ with ionotropic receptors. In-
deed, the C-terminus of D5, but not D1 receptor interacts
with the C-terminus of the Q2 subunits of GABA-A receptors
[64]. An inhibitory cross-talk between these two receptors was
observed. Similarly, two di¡erent regions of the D1 receptor
C-terminus can directly and selectively bind to the C-terminus
of NMDA receptor subunits, NR1-1a and NR2A [65]. D1
receptor activation has two e¡ects. On the one hand, it sup-
presses D1^NR1-1a interaction, allowing the coupling of
NR1-1a to phosphatidylinositol 3-kinase. On the other hand,
this interaction inhibits NMDA receptor membrane expres-
sion [65].
5. Concluding remarks
The reader will agree that these results show that speci¢city,
selectivity and time course of GPCR signaling are indeed op-
timized by the sca¡olding of functional multi-protein com-
plexes associated with their C-terminal tails. Although the
C-terminal tails of GPCRs were promptly recognized as being
important for the ¢ne-tuning of G protein activation, their
roles as ‘magic’ hooks to ¢sh for GPCR-associated proteins
have only recently been established. It is interesting to asso-
ciate this property with the observation that many GPCR
splice variants di¡er in their C-termini [66]. For example,
eight C-terminal splice variants have been described for the
5-HT4 receptor [67], and four C-terminus splice variants exist
for mGluR1 [68] and prostaglandin EP3 receptors [69]. These
variants bind to di¡erent intracellular sca¡olding/signaling
molecules that specify their transduction signals.
Although GPCR-associated proteins do not seem to be a
priority for most pharmaceutical companies, it is likely that
drugs able to disrupt or reinforce interactions within GPCR-
associated multiprotein complexes may constitute promising
tools for therapeutic treatment. Such compounds will be the
only possible means to di¡erentially modulate the activity of
GPCR splice variants that di¡er only in their C-terminal se-
quences.
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